



## **Leading Healthcare Executive joins Medlab Board**

- Seasoned (over 20 years) pharmaceutical experience
- Senior global participation (US/Europe/Australasia)
- Strong commercial acumen

**SYDNEY, August 08, 2022** - Medlab Clinical Ltd (ASX:MDC) (Medlab, the Company), an Australian biotech using delivery technology to enhance medicines effectiveness, is pleased to announce that it has appointed Mr. Mohit Gupta as an independent Non-Executive Director of the company, effective 08 August 2022.

Mohit is a seasoned professional with more than 20 years' experience in various roles and geographies, with last 10 years in Pharmaceuticals in various commercial capacities based in Australia and Switzerland, including business development roles at Viatrix Pharmaceuticals.

Previously Mohit has worked in Supply Chain, Projects, and Procurement. He has experience in large deals for acquisition and divestments. Led teams for various projects with conflicting priorities and timelines to achieve the goals.

Mohit has a Bachelor of Commerce Degree, and a Master of Business Administration in Finance.

"We are delighted to welcome Mohit to the Board of Medlab Clinical," said Mr Michael Hall, Chairman of Medlab Clinical. This is an important appointment that broadens the Board's skill set and is aligned with our strategic focus to commercialise novel pharmaceutical products and expand further into overseas markets".

"Mohit's global focus, especially within US Global Pharma space, will be invaluable as we embark on the next stage of our journey".

**ENDS**

### **Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

### **About Medlab Clinical:**

Medlab Clinical LTD (ASX:MDC) is pioneering the development and Commercialisation of a delivery technology, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability.

Medlab's pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

Patented lead drug candidate NanaBis™ has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain.

NanoCelle®, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory. NanoCelle® is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit [www.medlab.co](http://www.medlab.co)

**Medlab** – *better medicines, better patient care*